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Abstract 
A series of alternative Zn-binding groups were explored in the design of phenyl-4-yl-
acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Most of the 
synthesized compounds were less effective than the parent hydroxamic acid. However, the profile 
of activity shown by the analogue bearing a hydroxyurea head group, makes this derivative 
promising for further investigation.  
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Over the last 10 years the reversible acetylation of histones and other proteins has emerged as an 
important regulatory mechanism implicated in cell proliferation and has been identified as a 
valuable target for anticancer drug design. 
Acetylation is executed by histone acetyltransferases and is reversed by histone deacetylases 
(HDACs).1 Eighteen mammalian HDAC enzymes have been identified so far, which can be 
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subdivided into two families according to a cofactor (Zn2+ for Classes I, II and IV or NAD+ for 
Class III) for activity.2 
A number of HDAC inhibitors reached clinical trials, and five of them were approved by FDA: 
Vorinostat (Zolinza; 2006), Romidepsin (Istodax; 2009) both for use in peripheral T-cell lymphoma 
(CTCL) with the latter also for use in peripheral T-cell lymphoma (CTCL) (2011). Belinostat 
(Beleodaq; 2014) and Chidamide (Epidaza; 2015) both for use in CTCL and, more recently, 
Panobinostat (Farydak; 2015) for use in multiple myeloma.3 They all fit in the widely accepted 
HDAC pharmacophore model for HDAC inhibitors characterized by a cap group, a linker chain and 
a zinc binding group (ZBG).4 Based on molecular modelling studies involving the histone 
deacetylase-like protein (HDLP), these molecules appear to bind in a pocket of the HDAC active 
site in such a way that the metal binding moiety (a hydroxamic acid for SAHA, Belinostat and 
Panobinostat, a thiol derivative for Romidepsin and a benzamide for Chidamide), coordinates the 
catalytic zinc ion at the end of the pocket. Binding of the Zn2+ ion has proven to be crucial for the 
activity.  
Since the discovery of SAHA, structural studies to identify novel HDAC inhibitors have mainly 
focused on modifications of the linker or the cap group, while less attention has been paid to the 
metal binding group.  
Hydroxamic acid derivatives represent the most studied and successful class of HDAC inhibitor 
drug candidates. However, although very powerful, they suffer from poor metabolic stability and a 
rapid excretion.5,6 The different clinical applications of this class of drugs, such as CNS, 
inflammatory and HIV diseases, require a renewed effort in the search for new ZBG. 
Several efforts have been made to replace the hydroxamic acid with alternative chemical moieties 
that could also further improve the isoform selectivity of HDAC inhibitors.7-11 
 
As part of a previous research program aimed at studying new HDAC inhibitors, we have 
developed a series of hydroxamic acid-based compounds, characterized by a cinnamic spacer 
capped with a substituted phenyl group (1, Figure 1).12 Extensive research has been conducted on 
the derivatization of the cap group, to optimize drug-target interactions.12-14 
 
CONHOH
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Figure 1. General structure of compounds 1. 
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Recently, we have initiated the search for moieties that would retain the zinc-binding properties and 
enzyme inhibitory activity of the hydroxamic acid group. In this paper we report the attempts made 
to modify the ZBG-functionality of the 4-vinylbiphenyl scaffold. 
 
A series of analogues incorporating non-hydroxamic groups was designed to probe the potential of 
various ZBGs. Indeed, very stringent constraints should be satisfied in order to have zinc binding 
(as with the hydroxamic acid group), and also interactions with amino acid residues of the enzymes 
to have a strong binding affinity.15 The N-hydroxyurea group appears to be an interesting possible 
replacement for the hydroxamate group commonly found in HDAC inhibitors, because both groups 
display an identical binding mode.15-17 SAHA N-hydroxyurea derivative was found to show anti-
HDAC activity even though it was much less effective than SAHA.16 To investigate the effect of 
the hydroxyurea group on the 4-vinylbiphenyl scaffold, compound 6 was synthesized starting from 
acid 2 (weak Zn2+ coordinator), which was tested for its HDAC inhibitory activity as well. The acid 
was quantitatively converted into the corresponding isocyanate 4 by treatment with 
diphenylphosphorylazide (DPPA) in dry CH2Cl2. This latter was reacted with hydroxylamine in 
toluene to give the hydroxyurea 6. The same strategy was used to prepare the O-benzyl derivative 7 
(Scheme 1). 
Isocyanate 4 was also used as an intermediate to prepare semicarbazide 5, based on the 
consideration that a SAHA semicarbazide derivative was found to be active as HDAC inhibitor.16 
As other derivatives with a hydrazide group showed HDAC inhibitory activity,18 we also replaced 
the hydroxamic acid moiety of reference compound 1a with a hydrazide counterpart. Accordingly, 
compound 3 was prepared by condensation of acid 2 with hydrazine in the presence of HOBt and 
EDC (Scheme 1).19  
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(a) DPPA,  TEA, CH2Cl2, reflux, 7h, 100%; (b) HOBT, EDC, NH2NH2.H2O, 
cyclohexene, acetonitrile, 0-10 °C, 10 min.,  77%; (c) NH2NH2.H2O, toluene, 80 
°C, 1h, 63%; (d) NH2OH, toluene, reflux, 1h, 53% (e) O-benzylhydroxylamine, 
toluene, reflux, 3.5h, 23%.
 
Scheme 1. Synthesis of compounds 2-7. 
 
Other groups were selected based on the concept that it is possible for them to bind to the zinc ion. 
Sulfur ligands are well known to bind tightly to Zn containing enzymes. In particular, HDAC 
inhibitors with α-thioacetate20 as well as α-thioacetoxyketone moiety in place of the hydroxamic 
acid showed higher inhibition of the enzyme than SAHA.21,22 Based on these results, the synthesis 
of analogues harbouring an α-thioacetoxyketone as a ZBGon the phenyl-4-yl-acryloyl scaffold was 
performed. Heck condensation between 4-bromobiphenyl 8 and but-3-en-2-one afforded ketone 9 
that was brominated with pyrrolidone hydrotribromide to obtain 10. Treatment of this latter with 
potassium thioacetate gave the desired thioacetoxyketone 11 in good yield (Scheme 2). 
We also speculated that another possible ZBG could be the thiocyanate group, which is known to 
bind the Zn ion through the nitrogen atom.23 Thus, compound 14 was prepared from 4-
bromobiphenyl 8, which was coupled with 3,3-diethoxypropene to obtain aldehyde 12 in 78% yield. 
Reduction by NaBH4, followed by treatment with PBr3 afforded the bromide 13 in 88% overall 
yield. Reaction with silica gel-supported potassium thiocyanate24 afforded compound 14 in good 
yield. (Scheme 2). 
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(a) But-3-en-2-one, Palladium acetate, tri(o-tolyl)phosphine, TEA, 100-110°C, 12h, 42%; (b) Pyrrolidone
hydrotribromide, THF, rt, 24h, 41%; (c) potassium thioacetate, DMF, rt, 2.5h, 56%; (d) 3,3-Diethoxypropene,
Bu4NOAc, K2CO3, KCl, Pd(OAc)2, DMF, 100°C, 5h, 78%; (e) NaBH4, EtOH, rt, 30 min, 98%; (f) PBr3, Et2O, rt, 
1h, 90%; (g) potassium thiocyanate-SiO2, hexane, 50°C, 3.5h, 78%.
b c
e,fd
8
9 10 11
12 13 14
 
 
Scheme 2. Synthesis of compounds 11 and 14. 
 
During the past years, Cohen’s group has investigated several new cyclic ketones and lactones as 
ZBGs for Zn-dependant enzymes. Among them, they proposed some 6-membered cyclic 
hydroxamic and thiohydroxamic acids.25 The purpose to investigate the effect of a 5-membered 
cyclic hydroxamic acid, which should be the closest structural analogue of hydroxamic acid, 
prompted us to synthesize compound 17 (Scheme 3). When this work was already in an advanced 
stage, the same group was reported as a novel ZBGs for HDAC inhibitors.26  
 
CHO
O
O
N
O
OH
a b
15 16 17
(a) Butyrolactone, NaOMe, toluene, -10°C for 5 min, then rt for 1.5 h, 89%; (b) NH2OH.HCl, EtONa, reflux, 3.5h, 20%.
 
 
Scheme 3. Synthesis of compound 17. 
 
The synthesized compounds were tested for their inhibitory activity towards HDAC2 isoform 
(Table 1), and for cell growth inhibition against a panel of tumor cell lines of different tissue origin: 
NB4 (human acute promyelocytic leukemia), H460 (human lung carcinoma), HCT116 (human 
colon cancer), IGROV-1 and its subline resistant to cisplatinum IGROV-1/Pt1(human ovarian 
carcinoma) (Table 2). 
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Table 1  HDAC2 inhibitory activity of synthesized compounds. 
 
Cpd HDAC2a (IC50, µM) 
SAHA 0.15±0.02 
1a 0.82±0.14 
2 > 5 
3 > 5 
5 > 5 
6 1.05±0.62 
7 > 5 
11 > 5 
14 > 5 
17 > 5 
a
 HDAC activity was determined using HDAC2 from HeLa cells as indicated in SI 
 
Table 2 Cell growth inhibition (IC50, µM) of synthesized compounds and reference HDAC 
inhibitor (SAHA) against a panel of tumor cell lines. 
 
cpd IGROV-1 IGOV/Pt1 HCT116 NB4 H460 
IC50 (µM)a 
SAHA 2.2±0.3 2.2±0.2 1.2±0.1 0.70±0.03 3.4±0.8 
1a 3.5±0.6 4.0±0.4 1.6±0.3 0.9±0.1 5.4±0.1 
2 - - >20 >10 >20 
3 7.6±0.2 25.1±5.9 11.9±1.2 7.1±0.7 >20 
5 14.5±0.3 26.7±0.3 16.4±3.0 9.8±0.9 >20 
6 3.5±0.3 6.7±0.2 4.0±0.7 1.96±0.1 9.5±0.4 
7 40±1 >> 50 40±3 > 20 > 20 
11 26.4±0.8 18.7±0.6 14.0±1.5 > 20 >20 
14 3.8±0.6 58.1±2.6 12.6±3.8- > 20 9.4±1.6 
17 >> 60 >> 60 > 20 > 20 > 20 
a Cells were exposed for 72 h. Cell growth inhibitory activity was measured by cell counting and expressed as concentration required 
for 50% inhibition of cell growth (IC50). IC50 values were determined by dose–response curves. Results are the means ± SD of three 
independent experiments. 
 
Most of the synthesized compounds were characterized by a low activity (compared to SAHA) in 
terms of both HDAC inhibition and cell growth inhibition. In spite of a lack of enzymatic activity, 
compounds 3, 5, 11, and 14 showed a moderate cell growth inhibition, most likely related to the 
inhibition of multiple targets. In fact, there appears to be a common opinion that inhibitors 
containing metal binding groups can be prone to widespread off-target enzymatic inhibition, due to 
non-specific metal binding.27 
The introduction of an O-benzyl hydroxyurea moiety (compound 7) and of a 5-membered cyclic 
hydroxamic acid (compound 17) led to a loss of activity Only compound 6, bearing a hydroxyurea 
as ZBG, exhibited activity comparable to the parent compound 1a, both in HDAC2 and cell growth 
inhibitions.  
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Thus, the profiling of 6 was carried out also against HDAC 1 and HDAC 6 isoforms, using SAHA 
as a reference compound. The results (HDAC1: compound 6, IC50 1.31 ± 0.21 µM. SAHA, IC50 
0.12 ± 0.01 µM; HDAC6: compound 6, IC50 1.05 ± 0.09  µM. SAHA, IC50 0.07 ± 0.01 µM) 
suggested that the compound was a multi-HDAC inhibitor, its activity against HDAC 1 and 6 being 
comparable to the activity against HDAC 2 (see SI for details). 
A structural rationalization study was conducted in order to understand the main interaction features 
of compounds 1a and 6 with the enzyme. The molecular docking protocol adopted here has been 
validated in the past through the re-docking of the co-crystallized SAHA within the HDAC2 protein 
structure.28 Both the hydroxamate and N-hydroxyurea groups of compound 1a (ChemPLP score of 
the best ranked pose: 69.8; 100% convergent docking solutions) and 6 (ChemPLP score of the best 
ranked pose: 75.4; 100% convergent docking solutions), respectively, were involved in zinc 
chelation. Polar interactions of these chelating groups with neighbor residues (His146, Tyr308) 
were also observed. The additional nitrogen atom present in compound 6 made a hydrogen bond 
with Gly154. The zinc binding groups of both molecules were connected to two phenyl rings, the 
first one stabilized by hydrophobic interactions with Phe105, Phe210, and Leu276, the second one 
solvent exposed in both cases (Figure 2).  
 
 
A B 
 
 
Figure 2. HDAC2 in complex with compound 1a (best-ranked pose, purple balls & sticks, A), and 
compound 6 (best-ranked pose, black balls & sticks, B). The protein is reported as gray ribbons. 
Zinc ion is indicated as a gray ball. Key residues for ligands stabilization are labeled.  
 
In conclusion, we explored alternative ZBGs in the design of phenyl-4-yl-acrylohydroxamic acid 
derivatives as HDAC inhibitors. Most of the synthesized compounds were less effective than the 
parent hydroxamic acid 1a. However, the profile of activity shown by compound 6, bearing a 
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hydroxyurea head group, makes this derivative a promising candidate for further investigation, also 
taking into account the potential improvement in terms of bioavailability/metabolism of 
hydroxyurea over hydroxamate. 29, 30 
  
Supplementary data  
 
Supplementary data associated with this article can be found, in the online version, at  
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